- Record: found
- Abstract: found
- Article: not found
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.
Jamie E Chaft
1 ,
Valerie Rusch ,
Michelle S Ginsberg ,
Paul K Paik ,
David J Finley ,
Mark G Kris ,
Katharine A R Price ,
Christopher G Azzoli ,
Matthew G Fury ,
Gregory J Riely ,
Lee M Krug ,
Robert J Downey ,
Manjit S Bains ,
Camelia S Sima ,
Nabil Rizk ,
William D Travis ,
Naiyer A Rizvi
Aug 2013
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC.